Review papers with raw data transparency

Paper and scope

The paper Impact of cigarette smoke on the functions of mesenchymal stem cells (Cell Transplantation, 2025) is a literature review collating 127 references to summarize how cigarette smoke (combustible cigarettes, CSE, 3R4F standard reference, and ENDS components) and major toxicants (nicotine, aldehydes, heavy metals, tobacco specific nitrosamines) affect MSC biology across sources (ADMSCs, BM-MSCs, DPSCs, PDL-MSCs, LR-MSCs, hMSCs), using in vitro, ex vivo, and in vivo data. The authors conclude that smoke exposure impairs MSC regenerative and immunomodulatory functions and recommend standardized exposures and clinical validationPavlovic et al 2025 abstract and scope

What the review synthesizes (key factual claims with source anchor)

• Consistent impairment of MSC proliferation and viability across MSC sources in response to cigarette smoke extracts or reference smoke (dose dependent; low-level effects sometimes reversible; high-dose cytotoxic) — supported by multiple primary studies and synthesized in the reviewProliferation and viability synthesis
• Oxidative stress and mitochondrial dysfunction as central mechanisms (elevated ROS, depletion of antioxidant defenses), linked to downstream activation of inflammatory programs including NLRP3 inflammasome — supported by transcriptomics and functional rescue experiments (MCC950 restoration of HSPC support) in cited studies summarized in the reviewNLRP3 and ROS evidence
• Disruption of specific signaling pathways important for MSC function: reduced Smad2/3 phosphorylation in TGF-β signaling, dysregulated MAPK/ERK and PI3K/AKT, altered JAK/STAT and miRNA-RUNX2 axes affecting osteogenesis — mechanisms pulled from in vitro molecular analyses collected in the reviewSignaling pathway disruptions
• Functional endpoints affected: impaired osteogenic and chondrogenic differentiation (reduced ALP activity, RANKL, RUNX2 perturbation, decreased COL1A1), reduced migration (CD44, CTTN), and altered immunomodulation (shift to proinflammatory cytokine profile, reduced IL-10/IDO) — repeatedly reported across studies summarized in the reviewDifferentiation and immunomodulation effects

Strengths of the review

1. Comprehensive collation: 127 references across molecular, cellular, in vivo and clinical ex vivo studies giving a broad, multi-level picture of smoke effects on MSCsComprehensive literature synthesis
2. Mechanistic linkage: connects specific toxins to discrete molecular readouts (ROS, Smad, NLRP3) and to cell functional outcomes (ALP, migration, cytokine profiles).
3. Translationally relevant recommendations: highlights donor and recipient smoking history as clinically important for MSC therapies.

Limitations and critical caveats (why be skeptical)

• Heterogeneity of primary studies: methods for CSE preparation, cigarette types (3R4F vs commercial), concentrations, exposure durations, and MSC sources vary widely — this makes quantitative integration and inference of physiological relevance difficult; the authors explicitly note this limitationExposure heterogeneity caveat
• Predominance of in vitro data: many experiments use supraphysiological CSE concentrations or acute exposures that may not reflect chronic human exposures; few robust clinical in vivo studies directly compare MSCs from matched smokers vs non-smokers under physiological conditions — the review calls for more clinical validationNeed for clinical validation
• Potential publication and selection bias: positive results (harmful effects) may be over-represented; negative or null findings less likely published — review notes heterogeneity but cannot correct for publication bias.
• Confounding donor factors: age, comorbidities, alcohol, medication, and environmental exposures in smoker populations may confound MSC phenotype changes; few primary studies fully adjust for these.
• Limited direct causal human evidence: while mechanistic in vitro and animal data are persuasive, robust human in vivo functional endpoints (e.g., randomized transplant outcomes comparing smoker vs non-smoker MSCs) are absent.

Reproducibility and data transparency

The review collates published datasets but contains no new raw data; reproducibility across primary papers is constrained by inconsistent reporting of CSE preparation, concentrations, and exposure metrics — the review scores reproducibility modestly and recommends standardized exposure protocols and biomarkers (e.g., defined nicotine, formaldehyde, and acrolein concentrations, ROS assays, ALP/RUNX2 readouts)Reproducibility limitations

Where the review is most useful

• Designers of MSC clinical protocols should screen donor/recipient smoking history and consider functional testing of donor MSCs (proliferation, migration, ALP, cytokine suppression assays) prior to use.
• Scientists studying MSC biology: gives a prioritized list of candidate pathways (NLRP3, TGF-β/Smad, MAPK/ERK, PI3K/AKT, miRNA-1305/RUNX2, Cx43, CD44/CTTN/BIRC5) to interrogate in mechanistic experiments.
• Regulatory and standardization efforts: motivates an agreed-upon CSE/exposure standard and reporting checklist for MSC smoke-exposure research.

Concrete suggestions to improve the field (and what would falsify the review's main claim)

1. Standardize CSE preparation and report key metrics (nicotine, acrolein, formaldehyde per mL) so cross-study meta-analysis becomes feasible.
2. Perform prospective clinical studies comparing MSCs isolated from matched smokers and non-smokers with blinded functional assays and transplantation outcomes in relevant animal models or human trials; adjust for age and comorbidities.
3. Test targeted pathway rescue studies in physiologically relevant in vivo models (e.g., NLRP3 inhibitors like MCC950, antioxidants that restore mitochondrial function) with functional endpoints (engraftment, bone healing, immunomodulation) to demonstrate causality — as noted in the review, MCC950 restored HSPC support in one study, a promising mechanistic validationMCC950 rescue evidence
4. What would disprove the review claim: robust, blinded clinical data showing smoker-derived MSCs perform indistinguishably from non-smoker MSCs across standardized in vitro functional assays and in vivo engraftment/therapeutic endpoints, with no ROS/signaling differences under physiological exposure regimes.

Quick evidence table (high-level)

Paper scoring (objective, derived from review metadata)

• Novelty 6/10 — synthesizes previously scattered observations into a contemporary, useful clinical-translational framing, not a radical new discovery.
• Scientific quality 8/10 — thorough, balanced, and well-referenced for a review, but constrained by underlying heterogeneous primary literature.
• Generality 7/10 — covers multiple MSC types and exposures, broadly relevant to regenerative medicine.
• Usefulness 8/10 — practical recommendations for clinicians and researchers and highlighting actionable knowledge gaps.
• Reproducibility 5/10 — limited because primary studies differ methodologically; review does not supply new standard data.
• Explanatory depth 8/10 — mechanistic focus on ROS, NLRP3, Smad, and other pathways gives depth beyond descriptive reporting.

Practical recommendations for researchers and clinicians

1. Record donor and recipient smoking history as mandatory metadata in MSC trials and biobanking.
2. Implement standardized functional screens for MSC products prior to clinical use (viability, proliferation curve, ALP, migration assay, IDO/IL-10 secretion assay).
3. Use physiologically calibrated CSE exposures guided by measured concentrations of nicotine, acrolein, formaldehyde, and heavy metals for in vitro modeling; report mg or µg per mL units and LC-MS quantitation.
4. Pursue mechanistic rescue experiments in vivo e.g., NLRP3 inhibition (MCC950) or mitochondrial antioxidants to test reversibility of smoke-induced MSC dysfunction.

Confidence statement and what would change it

Confidence in the review conclusions is moderate: the preponderance of consistent mechanistic and functional data from multiple groups supports smoke-induced MSC dysfunction, but heterogeneity of exposures and limited clinical data lowers certainty. High-quality clinical studies showing no persistent functional deficit in smoker-derived MSCs would substantially lower confidence; conversely, well-controlled in vivo rescue experiments restoring function would raise confidence in causality.

Interactive next steps

Author review links

Review author Dragica Pavlovic • Review author Dragana Papic • Review author Danijela Niciforovic • Review author Vladislav Volarevic